Silence Therapeutics received designations for its divesiran program from the FDA, leading to stock price movement.

The entities involved

• Silence Therapeutics →

  UK business

  • Cantor Fitzgerald began coverage and issued rating, and Morgan Stanley upgraded price objective and rating for Silence Therapeutics.Tue 12:33
• FDA →
  • The illegal U.S. vape market is estimated to be worth $9 billion, fueled by unauthorized imports from China, while products must meet FDA authorization standards.Sun 20:36
  • VDPHL01 and Veradermics, Incorporated are seeking FDA approval for their lead therapies targeting hair loss.Sun 20:31

Related events

• Rocket is utilizing Nasdaq for investor evaluation and the FDA reviewed Phase 2 efficacy data for its product RP-A501.Sep 23
• uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.Sep 9
• Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.Oct 8